PRAX Praxis Precision Medicines Inc.

Biotech Analyst Ratings

Latest News

1. 23 May 2022 Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

   BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of Jill DeSimone to its board of directors.
   

   "We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impressive background as a global business leader for multi-billion-dollar products, unique insights into product strategy and portfolio prioritization, and breadth of experience advocating for excellence in patient care," said Marcio Souza, president and…

   View Full Article
2. 11 May 2022 Praxis Precision Medicines to Present at Upcoming Investor Conferences

   BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:
   

   • Citi Biotech Virtual Co-Panel Day
           º  ‘Mood Disorders/Mental Health' panel on Wednesday, May 18, 2022 at 11:00 a.m. ET
           º  ‘Movement Disorders/Epilepsy' panel on Wednesday, May 18, 2022 at 3:30 p.m. ET
     
     
   • H.C. Wainwright Global Investment Conference
           º  Company presentation available on Tuesday, May 24, 2022 at 7:00 a.m. ET

   The events…

   View Full Article
3. 09 May 2022 Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results

   PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study
   

   PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results expected in June 2022

   Epilepsy Day showcases largest targeted epilepsy portfolio in industry

   Cash and investments of $222.5 million as of March 31, 2022 supports runway into 3Q23

   BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update, including a video highlighting recent…

   View Full Article
4. 09 May 2022 Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients

   PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study
   

   Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by statistically significant difference in the placebo-controlled randomized withdrawal phase

   PRAX-944 continues to be generally well-tolerated

   BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced positive topline results from Part B of its Phase 2a study evaluating the safety and efficacy…

   View Full Article
5. 04 May 2022 Praxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference

   BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 5:00 p.m. ET (2:00 p.m. PT).
   

   The fireside chat will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company's website at www.praxismedicines.com. A replay of the webcast will be available on Praxis' website for 90 days following the event.

   About …

   View Full Article